OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.



from The Medical News http://www.news-medical.net/news/20141231/OncoGenex-executes-initial-agreement-with-Teva-to-regain-rights-to-custirsen.aspx